CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38603654.
- Also identified by DOI 10.1200/PO.23.00677.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
NSCLC w/EGFRex19del & MET amp: durable intracranial + systemic response to amivantamab/osimertinib.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Acrylamides
- Antibodies, Bispecific
- Aniline Compounds
- Indoles
- Pyrimidines